Company has approved financial results for Quarter and year ending 31st March,2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Concord Drugs Limited reported strong financial performance for FY26. Standalone revenue grew 105% to Rs 7,585 lakhs from Rs 3,693 lakhs, while consolidated revenue increased 74% to Rs 7,874 lakhs from Rs 4,524 lakhs. Profit after tax surged 251% to Rs 103.74 lakhs (standalone) and 214% to Rs 105.50 lakhs (consolidated) compared to the previous year. EPS improved from Rs 0.30 to Rs 0.93 (standalone). However, the auditors flagged that trade receivables of Rs 4.14 crores have been outstanding for over 2 years without any provision for doubtful debts, and cash flow from operations turned negative at Rs 737 lakhs versus positive Rs 316 lakhs in the prior year.
The company showed exceptional revenue and profit growth, but the auditors' emphasis on long-unpaid receivables and negative operating cash flow raise concerns about collection efficiency and working capital management despite improved profitability.